CP and infection: In addition, accurate identification of the carbapenemase type harbored by a clinical isolate (i.e., KPC, OXA-48-like, VIM, IMP, and/or NDM) can inform optimal selection of novel β-lactam/β-lactamase inhibitor combination agents for treatment of infections caused by CP-CRE, as different carbapenemases are variably inhibited by these drugs (7).